Literature DB >> 10713723

Fas-independent apoptosis in T-cell tumours induced by the CD2-myc transgene.

E R Cameron1, J Morton, C J Johnston, J Irvine, M Bell, D E Onions, J C Neil, M Campbell, K Blyth.   

Abstract

Depending on the cellular context, the Myc oncoprotein is capable of promoting cell proliferation or death by apoptosis. These observations suggest that apoptosis in response to deregulated gene expression may represent a natural brake to tumour development. The pathways by which Myc induces apoptosis are as yet poorly characterised although recent observations on rat fibroblasts over-expressing Myc have demonstrated a requirement for the Fas pathway. To investigate the role of Fas in Myc-induced lymphomagenesis we backcrossed CD2-myc mice onto an lpr background. Rates of tumour development and phenotypic properties, including levels of apoptosis were indistinguishable from CD2-myc controls. Further, tumour cell lines derived from mice expressing a regulatable form of Myc showed inducible apoptosis at similar rates regardless of their lpr genotype. These results show that activation of c-myc and loss of Fas do not collaborate in T lymphoma development and that Myc-induced apoptosis in T-cells occurs by Fas-independent pathways.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10713723     DOI: 10.1038/sj.cdd.4400630

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  4 in total

1.  Inflammatory disease and lymphomagenesis caused by deletion of the Myc antagonist Mnt in T cells.

Authors:  Shala Dezfouli; Antony Bakke; Jie Huang; Anthony Wynshaw-Boris; Peter J Hurlin
Journal:  Mol Cell Biol       Date:  2006-03       Impact factor: 4.272

2.  Selection for c-myc integration sites in polyclonal T-cell lymphomas.

Authors:  Dana R Broussard; Jennifer A Mertz; M Lozano; Jaquelin P Dudley
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

3.  Inhibition of the intrinsic but not the extrinsic apoptosis pathway accelerates and drives MYC-driven tumorigenesis towards acute myeloid leukemia.

Authors:  Kari Högstrand; Eduar Hejll; Birgitta Sander; Björn Rozell; Lars-Gunnar Larsson; Alf Grandien
Journal:  PLoS One       Date:  2012-02-29       Impact factor: 3.240

Review 4.  MYC-y mice: from tumour initiation to therapeutic targeting of endogenous MYC.

Authors:  Jennifer P Morton; Owen J Sansom
Journal:  Mol Oncol       Date:  2013-03-08       Impact factor: 6.603

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.